Form 4: Hubert Joly Receives JNJ Deferred Share Units
Director Compensation Disclosure
Johnson & Johnson Director Hubert Joly was granted 975 deferred share units as part of the company's director compensation plan.
Summary
- Director Hubert Joly acquired 975 Deferred Share Units (DSUs) on April 23, 2026.
- The DSUs were granted under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
- These units are to be settled in cash upon the termination of the director's service.
- Following this transaction, the reporting person holds a total of 9,183.605 units, which includes accrued dividend equivalent rights.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations or financial strategy.
Positives
- Alignment of director interests with long-term shareholder value through equity-linked compensation.
Negatives
- None identified.
Risks
- Value of deferred share units is subject to the future market performance of Johnson & Johnson common stock.
Future Outlook
The DSUs will be settled in cash upon the termination of the reporting person's directorship, based on the fair market value of JNJ common stock at that time.
Industry Context
StockSavvy.ai notes that this is a routine disclosure of director compensation, consistent with standard corporate governance practices for large-cap pharmaceutical companies.
Comparison to Industry Standards
- The use of deferred share units for non-employee directors is a standard practice among S&P 500 companies to ensure long-term alignment.
- The structure of the grant is consistent with typical compensation packages for board members at peer companies like Pfizer or Merck.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of deferred share units under the Amended and Restated Deferred Fee Plan for Directors. | 2026-04-23 | Standard alignment of director compensation with shareholder interests. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard component of director remuneration.
Next Steps
- No further action required by the reporting person other than future periodic reporting of holdings.
Key Dates
| Date | Description |
|---|---|
| 2025-12-03 | Date of Power of Attorney execution. |
| 2026-04-23 | Date of the DSU grant transaction. |
| 2026-04-27 | Date of filing. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.